Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older.
- People who have been formally diagnosed with rheumatoid arthritis (RA) using a recognised set of international medical guidelines (ACR/EULAR 2010 criteria).
- People whose RA is currently rated as moderate to high in activity, based on a specific disease measurement tool that uses a blood marker called CRP (a score known as DAS-28-CRP, which must be above 3.2).
- People who have been taking one or more standard (non-biologic) disease-modifying medications for their RA on a stable, unchanged dose for at least the past 3 months.
Who may not be able to join:
- People currently receiving biologic disease-modifying medications for their RA (a specific category of stronger, injectable or infused treatments).
- People taking any other anti-inflammatory medications.
- People taking any antioxidant supplements or medications.
- Women who are pregnant or currently breastfeeding.
- People who have other rheumatological or inflammatory conditions, or any form of cancer.
- People who smoke.
- People with thyroid conditions.
- People with significantly reduced liver function (based on a specific blood test result) or significantly reduced kidney function (based on a kidney filtration rate measurement falling below a certain threshold).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lamia El-Wakeel, Professor of Clinical Pharmacy, Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University
Phone: +201023669009
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring: • Serum Sirtuin 1(SIRT1) • Serum Myeloperoxidase (MPO) • Serum C-reactive protein (CRP)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.